The leading drug firms in the world are making their way to artificial intelligence (AI) to enhance the “hit and miss” business model of discovering new drugs, with GlaxoSmithKline revealing a new $43 Million contract in the same field this week. Other pharmaceutical majors comprising Johnson & Johnson, Merck & Co., and Sanofi are also looking at the potential of AI to assist streamline with the drug discovery procedure.
The goal is to tie up together the machine learning systems and modern supercomputers to forecast how molecules will react and how likely they are close to create a helpful medicine, thereby saving money and time on needless tests. AI networks already play a crucial role in other advanced areas such as the facial recognition software and development of driverless cars.
“Most of the large pharma firms are commencing to understand the potential of this method and how it assists in enhancing efficiencies,” claimed Chief Executive of privately owned Exscientia, Andrew Hopkins, who declared the new joint venture with GSK. Hopkins, who previously used to labor at Pfizer, claimed that the AI system of Exscientia can offer drug candidates in almost a time frame of 1 quarter and at the cost required for traditional approaches of 1 quarter.
The Scotland-based firm, which also made a contract with Sanofi back in May, is one of the most successful start-ups that are using AI for the sole purpose of drug research. Others comprise the U.S. firms Numerate, Berg, Atomwise, and twoXAR as well as the UK’s BenevolentAI. “In pharma’s mind, these firms are fundamentally digital biotechs that they can strike joint ventures with and which help the pipeline going on smoothly,” said Head of life sciences in London at Silicon Valley Bank, Nooman Haque.
“If this technique actually proves itself, you may commence to view M&A with pharma, and a quicker combination of these AI engines into pharma R&D.” It is not the first time that drug makers have looked up on high-tech solutions to fuel productivity of R&D. The roll out of towering throughput screening generated a huge amount of leads in the early 2000s.
Well, let us see how these technological advancements in the medical sector might come handy.